Severe eosinophilic granulomatosis with polyangiitis responding to a combination of rituximab and mepolizumab
- PMID: 35970248
- DOI: 10.1016/j.amjms.2022.07.007
Severe eosinophilic granulomatosis with polyangiitis responding to a combination of rituximab and mepolizumab
Abstract
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss Syndrome, is a multisystem antineutrophil cytoplasmic antibody (ANCA) positive vasculitis, characterized by the presence of chronic rhinosinusitis, asthma and prominent peripheral blood eosinophilia. Although the most commonly involved organ is the lung, followed by the skin, EGPA can affect any organ system. Herein, we present the complicated case of an 18-year-old male patient with severe life-threatening EGPA, with central nervous system, cardiac and gasterointestinal involvement, which was resistant to initial treatment with glucocorticoids and cyclophosphamide. The patient responded well, achieving complete remission after the addition of rituximab and mepolizumab to glucocorticoids and cyclophosphamide.
Keywords: Cyclophosphamide; Eosinophilic granulomatosis with polyangiitis; Glucocorticoids; Mepolizumab; Rituximab.
Copyright © 2022 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest There are no conflict sof interest regarding this manuscript.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
